Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Dilan Patel, MD, Tanner Johanns, MD PhD, Kathryn Trinkaus, PhD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4203.

https://doi.org/10.1182/blood-2018-99-113620

Published: 2018

Journal Articles

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Meagan Jacoby, MD, Reetom Bera, Theresa Fletcher, Mark A. Fiala, BS, Kathryn Trinkaus, PhD, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Daniel C. Link, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2018-99-115603

Published: 2018

Journal Articles

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Ramzi Abboud, MD BS, Kathryn Trinkaus, PhD, John F DiPersio, MD PhD, Camille N. Abboud, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 1967.

https://doi.org/10.1182/blood.V130.Suppl_1.1967.1967

Published: 2017

Journal Articles

Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant

Eric J. Duncavage, MD, Meagan Jacoby, MD PhD, Gue Su Chang, PhD, Christopher A Miller, PhD, Natasha Edwin, MD, Geoffrey L. Uy, MD, Joshua Robinson, Haley J Abel, PhD, Jin Shao, Kevin Elliot, Robert Fulton, Catrina Fronick, Michelle O'Laughlin, John F DiPersio, MD PhD, Timothy J Ley, MD, Kathryn Trinkaus, PhD, Timothy Aaron Graubert, MD, Matthew J. Walter, MD

Blood (2017) 130 (Supplement 1): 1669.

https://doi.org/10.1182/blood.V130.Suppl_1.1669.1669

Published: 2017

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood (2017) 129 (19): 2680–2692.

https://doi.org/10.1182/blood-2016-09-739722

Published: 2017

Includes: Supplemental data

Journal Articles

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

Ramzi Abboud, MD, Michael Slade, BA, Wenners Ballard, III, MD, Jesse Keller, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Camille N. Abboud, MD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Rizwan Romee, MD

Blood (2016) 128 (22): 3419.

https://doi.org/10.1182/blood.V128.22.3419.3419

Published: 2016

Journal Articles

Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation

Jason Thomas Romancik, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Kathryn Trinkaus, PhD, Rizwan Romee, MD

Blood (2016) 128 (22): 4698.

https://doi.org/10.1182/blood.V128.22.4698.4698

Published: 2016

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Ramzi Abboud, MD, Jesse Keller, MD, Michael Slade, BA, Michael P. Rettig, PhD, Stephanie Meier, John F. DiPersio, MD PhD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Camille N. Abboud, MD FACP, Khoan Vu, MD, Pavan Kumar Bhamidipati, MBBS,MD, Rizwan Romee, MD

Blood (2015) 126 (23): 3106.

https://doi.org/10.1182/blood.V126.23.3106.3106

Published: 2015

Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 1623.

https://doi.org/10.1182/blood.V120.21.1623.1623

Published: 2012

Journal Articles

The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide

Tzu-Fei Wang, MD, Mark Fiala, BS, CCRP, Rohan Ahluwalia, MD, Kathryn Trinkaus, PhD, Caitlin Moliske, Doug Cox, BS, Matthew Jaenicke, BS, Keith Stockerl-Goldstein, MD, Tanya Wildes, MD, Kenneth R. Carson, MD, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2012) 120 (21): 4050.

https://doi.org/10.1182/blood.V120.21.4050.4050

Published: 2012

Journal Articles

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Mark A. Schroeder, MD, Sandra Lopez, MD, Michael P. Rettig, PhD, Kathryn Trinkaus, PhD, Peter Westervelt, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 4095.

https://doi.org/10.1182/blood.V120.21.4095.4095

Published: 2012

Journal Articles

Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor

Mark A. Schroeder, MD, Michael P. Rettig, PhD, Sandra Lopez, MD, Fazia Mir, MD, Kathryn Trinkaus, PhD, Geoffrey L. Uy, MD, John F. DiPersio, MD, PhD

Blood (2011) 118 (21): 314.

https://doi.org/10.1182/blood.V118.21.314.314

Published: 2011

Journal Articles

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, Andre Goy, Stephanie E. Schneider, Catherine R. Keppel, Nina D. Wagner-Johnston, Kenneth R. Carson, Nancy L. Bartlett

Blood (2011) 118 (19): 5119–5125.

https://doi.org/10.1182/blood-2011-07-362475

Published: 2011

Includes: Supplemental data

Journal Articles

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Todd A. Fehniger, Geoffrey L. Uy, Kathryn Trinkaus, Alissa D. Nelson, Jeffery Demland, Camille N. Abboud, Amanda F. Cashen, Keith E. Stockerl-Goldstein, Peter Westervelt, John F. DiPersio, Ravi Vij

Blood (2011) 117 (6): 1828–1833.

https://doi.org/10.1182/blood-2010-07-297143

Published: 2011

Includes: Supplemental data

Journal Articles

Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Nina Wagner-Johnston, MD, Nancy L. Bartlett, MD, Jacqueline E. Payton, MD, PhD, Kathryn Trinkaus, PhD, Akash Sharma, MD, Justina Timm, MS, Richard F. Ambinder, MD, PhD

Blood (2010) 116 (21): 3127.

https://doi.org/10.1182/blood.V116.21.3127.3127

Published: 2010

Journal Articles

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Todd A Fehniger, MD, PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, Amanda F Cashen, MD, Kristie A Blum, MD, Timothy S. Fenske, MD, David D Hurd, MD, Andre Goy, MD, John F. DiPersio, MD, PhD, Nancy L Bartlett, MD

Blood (2009) 114 (22): 3693.

https://doi.org/10.1182/blood.V114.22.3693.3693

Published: 2009

Journal Articles

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Todd A Fehniger, MD, PhD, Sarah Larson, BA, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, John F DiPersio, MD, PhD, Amanda F Cashen, MD, David D Hurd, MD, Kristie A Blum, MD, Nancy L Bartlett, MD

Blood (2008) 112 (11): 2595.

https://doi.org/10.1182/blood.V112.11.2595.2595

Published: 2008

Journal Articles

Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.

Todd A. Fehniger, Alissa Nelson, Kathryn Trinkaus, Camille N. Abboud, Amanda F. Cashen, John F. DiPersio, Timothy A. Graubert, Timothy J. Ley, Michael H. Tomasson, Geoffrey L. Uy, Matthew J. Walter, Peter Westervelt, Ravi Vij

Blood (2007) 110 (11): 916.

https://doi.org/10.1182/blood.V110.11.916.916

Published: 2007

Journal Articles

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner

Angela C. Hirbe, Özge Uluçkan, Elizabeth A. Morgan, Mark C. Eagleton, Julie L. Prior, David Piwnica-Worms, Kathryn Trinkaus, Anthony Apicelli, Katherine Weilbaecher

Blood (2006) 109 (8): 3424–3431.

https://doi.org/10.1182/blood-2006-09-048686

Published: 2006

Includes: Supplemental data

NARROW

Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only